Differential Therapeutic Effects of Nateglinide and Acarbose on Fasting and Postprandial Lipid Profiles: A Randomized Trial

Diabetes Technology and Therapeutics

Volumn 17, Issue 4, 2015, Pages 229-234

  Zhou, Jian ^a   Deng, Zixuan ^a   Lu, Jingyi ^a   Li, Hong ^b   Zhang, Xiuzhen ^c   Peng, Yongde ^d   Mo, Yifei ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CYCLOHEXANE DERIVATIVE; LIPID; PHENYLALANINE;

ADULT; ARTICLE; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; CHINA; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; MIDDLE AGED; PROSPECTIVE STUDY; TIME;

ACARBOSE; ADULT; CHINA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 84925146435     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0299     Document Type: Article

References (23)

1. Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-316.
2. Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86:19L-22L.
3. Jeppesen J, Madsbad S: High triglyceride, low HDL-cholesterol and risk of coronary heart disease [in Danish]. Ugeskr Laeger 1996;158:6896-6901.
4. Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100-1107.
5. Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-159.
6. Gerich J, Raskin P, Jean-Louis L, et al.: PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093-2099.
7. Wang JS, Lin SD, Lee WJ, et al.: Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2011;33:1932-1942.
8. Zhou J, Li H, Zhang X, et al.: Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in Chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther 2013;15:481-488.
9. Ai M, Tanaka A, Ogita K, et al.: Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 2006;29:1180.
10. Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483-490.
11. Kado S, Murakami T, Aoki A, et al.: Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998;41:49-55.
12. Kojima Y, Kaga H, Hayashi S, et al.: Comparison between sitagliptin and nateglinide on postprandial lipid levels: the STANDARD study. World J Diabetes 2013;4:8-13.
13. Ogawa S, Takeuchi K, Ito S: Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab 2004;6:384-390.
14. Gao HW, Xie C, Wang HN, et al.: Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin 2007;28:534-539.
15. Lu J-M, Guo X-H, Lv X-F, et al.: Effects of nateglinide on postprandial plasma glucose excursion and metabolism of lipids in Chinese patients with type 2 diabetes: a 4-week, randomized, active-control, open-label, parallel-group, multicenter trial. Curr Med Res Opin 2012 July 19 [Epub ahead of print]. doi: 10.1185/03007995.2012.713340.
16. Scott R, Lintott CJ, Zimmet P, et al.: Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract 1999;43:179-185.
17. Mita T, Watada H, Shimizu T, et al.: Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007;27:2456-2462.
18. Vakkilainen J, Mero N, Schweizer A, et al.: Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002;18:484-490.
19. Chiasson JL, Josse RG, Leiter LA, et al.: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190-1193.
20. Baron AD, Eckel RH, Schmeiser L, et al.: The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism 1987;36:409-415.
21. Oyama T, Saiki A, Endoh K, et al.: Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb 2008;15:154-159.
22. Mine T, Miura K, Kitahara Y, et al.: Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharm Bull 2002;25:1412-1416.
23. Mori Y, Kitahara Y, Miura K, et al.: Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 2004;23:39-43.